Monarch Medical Technologies Announces New Chief Executive Officer
CHARLOTTE, N.C.--(BUSINESS WIRE)--Monarch Medical Technologies, the pioneer and leader in mitigating risk associated with drug dosing in hospitalized patients, today announced that Stuart Long has joined the company as its new chief executive officer. Formerly the global chief marketing and sales officer for CapsuleTech, Inc., Long has extensive experience in driving corporate growth and strategic objectives.
“Stuart shares our commitment and passion for ensuring patient safety by addressing and mitigating the risks that can be associated with certain drugs and point of care dosing processes. We value the talent he is able to bring to table and look forward to strong continued growth under his leadership.”
“Stuart was an ideal candidate for this position based on his deep technical and clinical expertise alongside his solid leadership skills in addressing the needs of health care professionals in the medical device and health information technology industries,” said Christophe Mallard, chairman of private investment firm Eigen Capital LLC, which owns Monarch Medical Technologies. “Stuart shares our commitment and passion for ensuring patient safety by addressing and mitigating the risks that can be associated with certain drugs and point of care dosing processes. We value the talent he is able to bring to table and look forward to strong continued growth under his leadership.”
With more than 20 years of experience in the medical device market, Long is well-versed in general management, sales, marketing, business development, professional services and R&D. Prior to his tenure at CapsuleTech, he was vice president of global product management at Philips Healthcare and has also held executive positions at healthcare IT-focused companies including Agfa Healthcare, AMICAS, FUJIFILM USA and Eastman Kodak.
“Monarch has made tremendous strides over the past year, and its team of industry experts have built a solid foundation for the EndoTool platform,” Long said. “I’m thrilled to be joining such an innovative organization, and to have the opportunity to help take the company to the next level.”
Monarch is the developer of the EndoTool® glucose management platform, a market-leading suite of blood glucose management software solutions recognized for the ability to provide unsurpassed patient-specific glycemic control across a broad population of patients. Most recently, the company received clearance in April from the U.S. Food and Drug Administration for EndoTool IV™, the latest system in the suite of products for both adult and pediatric patients.
About Monarch Medical Technologies
Monarch Medical Technologies is a privately held medical technology company founded by clinicians with a vision of dramatically improving hospital-based glucose management by replacing traditional “paper and pencil” linear protocols with individualized and predictive computer-based solutions. With the launch of its flagship product, the EndoTool Glucose Management System, the company pioneered the field of predictive therapeutic control technologies for managing drugs and processes of concern.
Formerly the EndoTool division of Hospira Worldwide, a leading Fortune 1000 healthcare company, the company was strategically acquired in October 2012 by private equity firm Eigen Capital Partners.